

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
10 September 2004 (10.09.2004)

PCT

(10) International Publication Number
WO 2004/076053 A2

- (51) International Patent Classification⁷: **B01J** Parsippany, NJ 07054 (US). **GIRGIS, Michael, John** [US/US]; 16 Skyline Drive, Montville, NJ 07045 (US).
- (21) International Application Number: PCT/US2004/005159 (74) Agents: **SAVITSKY, Thomas et al.**; Novartis AG, Corporate Intellectual Property, CH-4002 Basel (CH).
- (22) International Filing Date: 20 February 2004 (20.02.2004) (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
60/449,015 21 February 2003 (21.02.2003) US
60/449,016 21 February 2003 (21.02.2003) US
60/449,017 21 February 2003 (21.02.2003) US
- (71) Applicant (for all designated States except AT, US): **NOVARTIS AG** [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).
- (71) Applicant (for AT only): **NOVARTIS PHARMA GMBH** [AT/AT]; Brunner Strasse 59, 1230 Vienna (AT).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **PRASHAD, Mahavir** [US/US]; 27 Davenport Road, Montville, NJ 07045 (US). **KEM, Hang-Yong** [KR/US]; 2104 Harvest Court, Whippany, NJ 07981 (US). **HU, Bin** [CN/US]; 1275 Rock Avenue, D-6, North Plainfield, NJ 07600 (US). **SLADE, Joel** [US/US]; 14 Theresa Drive, Flanders, NJ 07836 (US). **KAPA, Prasad, Koteswara** [US/US]; 4 Faber Road,
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:
— without international search report and to be republished upon receipt of that report
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: **CHEMICAL PROCESS**

(57) Abstract: Improved processes for preparing intermediates useful for preparing antibacterial N-[1-oxo-2-alkyl-3-(N-hydroxy-formamido)-propyl]-(carbonylamino-aryl or -heteroaryl)-azacyclo4-7alkanes or thiazacyclo4-7alkanes, which have one or more of the following features: (1) make use of a particular I3-lactam intermediate; (2) which make use of a particular resolving agents, enantiomerically pure substituted propionic acids, especially (R)-2-butyl-3-hydroxypropionic acid; (3) which avoid the use of hydrogen peroxide; and (4) which facilitate selective debenzoylation reducing production of waste by-products.

WO 2004/076053 A2

DT12 Rec CT/PTO 1 4 MAR 2005
Case 4-32890A/891/892/USN

CHEMICAL PROCESS

Field of Invention

This invention is directed to a process for preparing certain antibacterial *N*-formyl hydroxylamine compounds.

Background of the Invention

PDF is a metallopeptidase found in prokaryotic organisms, such as bacteria. Protein synthesis in prokaryotic organisms begins with *N*-formyl methionine (fMet). After initiation of protein synthesis, the formyl group is removed by the enzyme PDF; this activity is essential for maturation of proteins. It has been shown that PDF is required for bacterial growth. See Chang et al., *J. Bacteriol.*, Vol. 171, pp. 4071-4072 (1989); Meinnel et al., *J. Bacteriol.*, Vol. 176, No. 23, pp. 7387-7390 (1994); and Mazel et al., *EMBO J.*, Vol. 13, No. 4, pp. 914-923 (1994). Since protein synthesis in eukaryotic organisms does not depend on fMet for initiation, agents that will inhibit PDF are attractive candidates for development of new anti-microbial and anti-bacterial drugs.


Co-pending Application Serial No. 10/171,706, filed June 14, 2002 (incorporated herein by reference in its entirety), PCT equivalent published as WO 02/102790 A1, discloses novel *N*-formyl hydroxylamine compounds that inhibit PDF and are therefore useful as antibacterial agents. The compounds disclosed therein are certain N-[1-oxo-2-alkyl-3-(*N*-hydroxyformamido)-propyl]-(carbonylamino-aryl or -heteroaryl)-azacyclo4-7alkanes or thiazacyclo4-7alkanes, which are described in more detail hereinafter. Additionally, PCT application WO 99/39704 discloses other *N*-formyl hydroxylamine derivatives that are antibacterial agents by virtue of their PDF inhibiting capabilities. Improved processes have been discovered for preparing intermediates useful for preparing these N-[1-oxo-2-alkyl-3-(*N*-hydroxyformamido)-propyl]-(carbonylamino-aryl or -heteroaryl)-azacyclo4-7alkanes or thiazacyclo4-7alkanes, which have one or more of the following features : (1) make use of a particular β -lactam intermediate; (2) which make use of particular resolving agents, e.g., enantiomerically pure substituted propionic acids, especially (R)-2-butyl-3-hydroxy-propionic acid; (3) which avoid the use of hydrogen peroxide (the use of hydrogen peroxide can be a safety concern because of its instability, therefore, this aspect of the invention is safer than

the prior art process); and (4) which facilitate selective debenzylation, reducing production of waste by-products.

Summary of the Invention


The present invention is directed to the novel processes for preparing certain intermediates which are useful to prepare certain *N*-formyl hydroxylamine compounds which are useful for inhibiting bacteria.

More specifically, the present invention is directed to a process for preparing a compound of formula (IX)




comprising Step A:


Contacting a compound of formula (I)



with a compound of the formula (II)




in a suitable solvent under conditions suitable to form a compound of the formula (III)




followed by asymmetric hydrogenation Step B:

Contacting the compound of formula (III) with hydrogen in the presence of a chiral ligand and a catalytic amount of a hydrogenation catalyst in a suitable solvent and under conditions suitable to form a compound of the formula (IV)




followed by Step C:

Contacting the compound of formula (IV) with a base such as a Grignard reagent in a suitable solvent under conditions suitable to form a compound of the formula (V)




followed by Step D:

Contacting the compound of formula (V) with a compound of the formula (VI)




in a suitable solvent, optionally in the presence of an activator under conditions suitable to form a compound of the formula (VII)




followed by Step E:

Contacting the compound of formula (VII) with a formylating agent in a suitable solvent under conditions suitable to form the compound of formula (VIII):



followed by Step F:

Converting the compound of formula (VIII) to the compound of formula (IX) by removing the hydroxy-protecting group using conventional hydrogenation techniques known in the art, e.g., by contacting the compound of formula (VIII) with hydrogen in the presence of a palladium catalyst, such as Pd/BaSO₄, to form the compound of formula (IX)



wherein

X is -CH₂-, -S-, -CH(OH)-, -CH(OR)-, -CH(SH)-, -CH(SR)-, -CF₂-, -C=N(OR)- or -CH(F)-;

Y is a hydroxyl-protecting group such as benzyl;

R is alkyl;

Ac is acetyl;


each of R₂, R₃, R₄, R₅, and R₁₀ and independently is hydrogen or alkyl, or (R₂ or R₃) collectively form a C₄-C₇cycloalkyl

R' is alkyl or aryl; and

n is 0-3, provided that when n is 0, X is -CH₂-.


Furthermore, the present invention discloses process for preparing a compound of formula (IX) making use of enantiomerically pure substituted propionic acids, especially (R)-2-butyl-3-hydroxy-propionic acid

More specifically, the present invention is directed to a process for preparing a compound of the formula (X)




comprising Step 1:

Resolution of a racemate of the compound of the formula (X), i.e., a compound of formula (XI):



by contacting the compound of formula (XI) with (R)- α -methylbenzylamine in a suitable solvent to form a (R,R)-diastomeric salt of formula (XII)




followed by Step 2:

Contacting the compound of formula (XII) with a biphasic mixture of an aqueous mineral acid and an organic solvent to form the compound of formula (XI),

wherein


each of R_2 , R_3 , R_4 and R_5 is, independently, hydrogen or alkyl; or R_2 and R_3 , collectively, form a C_4 - C_7 cycloalkyl, provided that R_4 and R_5 are different.

In addition, the present invention discloses process for preparing a compound of formula (IX) making use of a two-step process for preparing a compound of formula (XIII)




comprising Step i:

Contacting a compound of the formula (XIV)



with an alkoxide of p-methoxybenzyl alcohol, in a suitable solvent under conditions to form a compound of formula (XV)



followed by deprotection Step ii:

Contacting the compound of formula (XV) with a strong organic acid in a suitable solvent under conditions to form the compound of formula (XIII),

wherein

R_4 is alkyl;

Bn is benzyl; and

Me is methyl.


The present invention also provides a process for selectively converting the compound of formula (VIII) to the compound of formula (IX) by removing the hydroxy-protecting group, preferably benzyl, by contacting the compound of formula (VIII) with molecular hydrogen at sub-atmospheric pressures in the presence of a palladium catalyst in ethanol to form the compound of formula (IX).

Another aspect of the present invention is directed to a process for converting the compound of formula (XXV) to a compound of formula (XXVI) by removing hydroxyl-protecting group, preferably benzyl, by contacting the compound of formula (XXV) with a hydrogen transfer reagent comprising 4-methylmorpholine and formic acid in the presence of a palladium catalyst.

In addition to the above processes comprising multiple steps, e.g. Steps A-F, Steps 1-8, Steps i-ii, the present invention is directed to each of the steps individually, and to any two or more sequential steps.

Detailed Description of the Invention

In particular, the present invention provides a process for preparing intermediates useful in the preparation of a *N*-[1-oxo-2-alkyl-3-(*N*-hydroxyformamido)propyl]-(carbonylamino-aryl or -heteroaryl)-azacyclo₄₋₇alkanes or thiazacyclo₄₋₇alkanes, e.g., a compound of formula (IX)




wherein R₁, R₂, R₃, R₄, R₅, X and n are as defined above.

To convert the compound of formula (VIII) to the compound of formula (IX) Step F can be performed wherein the hydroxyl-protecting group is removed using conventional hydrogenation techniques known in the art, e.g., by contacting the compound of formula (VIII) with hydrogen in the presence of a palladium catalyst, such as Pd/BaSO₄.

Preferred compounds discussed herein, e.g., of formula (IX), are disclosed in U.S. Serial No. 10/171,706. For example, in the compounds described above, especially the

compound of formula (IX), the following significances are preferred individually or in any sub-combination:

1. R_1 is a heteroaryl of formula (II.1)



wherein

R_6 , R_7 and R_9 are hydrogen; and

R_8 is methyl or trifluoromethyl; or

R_6 , R_7 and R_8 are hydrogen; and

R_9 is fluoro; or

R_6 , R_8 and R_9 are hydrogen; and

R_7 is ethyl or methoxy; or

R_7 , R_8 and R_9 are hydrogen; and


R_6 is hydroxy; or

R_7 and R_8 are hydrogen;

R_6 is methoxy; and

R_9 is methyl; or

R_1 is a heteroaryl of formula (III.1)



wherein

R_6 , R_7 and R_9 are hydrogen; and

R_8 is fluoro or trifluoromethyl; or

R_6 , R_8 and R_9 are hydrogen; and

R_7 is ethyl;

preferably R_1 is a heteroaryl of formula (II.1),

wherein

R_6 , R_8 and R_9 are hydrogen; and

R_7 is ethyl

or R_1 is a heteroaryl of formula (III.1),

wherein

R_6 , R_7 and R_9 are hydrogen; and

R_8 is fluoro.

2. X is $-\text{CH}_2-$, $-\text{CH}(\text{OH})-$, $-\text{CH}(\text{OR})-$, $-\text{CF}_2-$ or $-\text{CH}(\text{F})-$, preferably X is $-\text{CH}_2-$;
3. R_2 , R_3 , R_5 are hydrogen;
4. R_4 and R_{10} are alkyl, preferably C_1 - C_6 alkyl for R_4 , such as *n*-butyl, and C_1 - C_5 alkyl for R_{10} such as *n*-propyl;
5. n is 1.

Unless otherwise stated, the following terms as used in the specification have the following meaning.

The term "alkyl" refers to saturated aliphatic groups, including cycloalkyl or substituted alkyl, preferably straight-chain, branched-chain and cyclic groups having from 1-10 carbons atoms. More preferably, "alkyl" or "alk", whenever it occurs, is a C_1 - C_7 alkyl, particularly, C_{1-4} alkyl. Examples of "alkyl" or "alk" include, but are not limited to, methyl, ethyl, *n*-propyl, isopropyl, *n*-butyl, isobutyl, sec-butyl, *t*-butyl, *n*-pentyl, neopentyl, *n*-hexyl or *n*-heptyl, cyclopropyl and especially *n*-butyl.

The term "cycloalkane" or "cycloalkyl" contains from 3- to 7-ring carbon atoms, and is, e.g., cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.

The term "aryl" or "Ar" refers to an aromatic carbocyclic group of 6-14 carbon atoms having a single ring including, but not limited to, groups, such as phenyl; or multiple condensed rings including, but not limited to, groups, such as naphthyl or anthryl; and, is especially, phenyl.

The term "heteroaryl" or "HetAr" refers to a 4- to 7-membered, monocyclic aromatic heterocycle or a bicycle that is composed of a 4- to 7-membered, monocyclic aromatic

heterocycle and a fused-on benzene ring. The heteroaryl has at least one hetero atom, preferably one or two heteroatoms including, but not limited to, heteroatoms, such as N, O and S, within the ring. A preferred heteroaryl group is pyridinyl, pyrimidinyl or benzodioxolanyl.

The aryl or heteroaryl may be substituted or unsubstituted by one or more substituents including, but not limited to, C₁-C₇alkyl, particularly, C₁-C₄alkyl, such as methyl, hydroxy, alkoxy, acyl, acyloxy, SCN, halogen, cyano, nitro, thioalkoxy, phenyl, heteroalkylaryl, alkylsulfonyl and formyl.

The term "heteroalkyl" refers to saturated or unsaturated C₁-C₁₀alkyl as defined above and, especially, C₁-C₄heteroalkyl which contain one or more heteroatoms, as part of the main, branched or cyclic chains in the group. Heteroatoms may independently be selected from the group consisting of -NR-, where R is hydrogen or alkyl, -S-, -O- and -P-; preferably -NR-, where R is hydrogen or alkyl; and/or -O-. Heteroalkyl groups may be attached to the remainder of the molecule either at a heteroatom (if a valence is available) or at a carbon atom. Examples of heteroalkyl groups include, but are not limited to, groups, such as -O-CH₃, -CH₂-O-CH₃, -CH₂-CH₂-O-CH₃, -S-CH₂-CH₂-CH₃, -CH₂-CH(CH₃)-S-CH₃ and -CH₂-CH₂-NH-CH₂-CH₂-.

The term "alkoxy", as used herein, refers to a C₁-C₁₀alkyl linked to an oxygen atom, or preferably, C₁-C₇alkoxy, more preferably, C₁-C₄alkoxy. Examples of alkoxy groups include, but are not limited to, groups such as methoxy, ethoxy, *n*-butoxy, *tert*-butoxy and allyloxy.

The term "acyl", as used herein, refers to the group -(O)CR, where R is alkyl, especially, C₁-C₇alkyl, such as methyl. Examples of acyl groups include, but are not limited to, acetyl, propanoyl and butanoyl.

The term "acyloxy", as used herein, refers to the group -OC(O)R, wherein R is hydrogen, alkyl, especially, C₁-C₇alkyl, such as methyl or ethyl, or phenyl or substituted alkyl as defined above.

The term "alkoxycarbonyl", as used herein, refers to the group -COOR, wherein R is alkyl, especially, C₁-C₇alkyl, such as methyl or ethyl.

The term "halogen" or "halo" as used herein, refers to chlorine, bromine, fluorine, iodine and, is especially, fluorine.


The term "thioalkoxy", as used herein, means a group -SR, where R is an alkyl as defined above, e.g., methylthio, ethylthio, propylthio, butylthio and the like.

The term "heteroalkylaryl", as used herein, means a heteroalkyl group, e.g., -O-CH₂-substituted with an aryl group, especially, phenyl. The phenyl group itself may also be substituted with one or more substituents, such as halogen, especially fluoro and chloro; and alkoxy, such as methoxy.


The term "alkylsulfonyl", as used herein, means a group -SO₂R, wherein R is alkyl, especially, C₁-C₇alkyl, such as methyl sulfonyl.

The term "enantiomerically pure" or "optically pure" means that the enantiomeric purity is greater than 55%, preferably greater than 80%, more preferably greater than 90%, and most preferably greater than 95%.


To prepare the compounds of formula (I), a compound of the formula



is contacted with a compound of the formula




in the presence of a catalytic amount of a catalyst, such as DABCO, DBU or DBN under sufficient conditions to form a compound of the formula



The above reaction is a Baylis-Hillman reaction.

The compound thus formed can then be reacted with acetic anhydride in a suitable solvent, in the presence of a base, such as 4-DMAP or a trialkylamine, e.g., triethylamine or tripropylamine, to form the compound of formula (I).


Preferably R_2 and R_3 are hydrogen and R_4 is *n*-propyl; which results in a compound such as formula (Ic)



The solvent used for the various steps A-F are typically organic solvents, although in some situations, aqueous/organic solvents can be used. Examples of suitable solvents include dioxane, methylene chloride, dichloromethane, toluene, acetone, methylethylketone, THF, isopropyl acetate, DMF, alcohols, especially higher-branched alcohols, such as *t*-butanol and the like.

For Step A, a typical temperature is about 10°C to about 50°C, preferably about 20°C to about 25°C. The solvent for Step A is typically THF, DMF, NMP and the like.

For asymmetric hydrogenation Step B, a typical temperature is about 10°C to about 50°C, preferably about 20°C to about 25°C. The solvent for Step B is not known to be critical and can be a wide variety of solvents, such as dioxane, methylene chloride, dichloromethane, toluene, acetone, methylethylketone, THF, isopropyl acetate, DMF, alcohols, especially higher-branched alcohols, such as *t*-butanol and the like. The hydrogen for Step is typically in the form of hydrogen gas and the Step B is typically preformed above atmospheric pressure, e.g., at about 40 psi to about 100 psi, more typically at about 45 psi to about 55 psi. The chiral ligand for Step B can be (2*S*,5*S*)-Me-Duphos, (1*R*,1'*R*,2*S*,2'*S*)-TangPhos and the like. (1*R*,1'*R*,2*S*,2'*S*)-TangPhos has the formula



The amount of Chiral ligand is typically about 1 mole % to about 15 mole % relative to the substrate. The hydrogenation catalyst is preferably homogenous. The hydrogenation catalyst is preferably a transition metal complex. Typical transition metal catalysts contain rhodium (Rh I) or ruthenium (Ru II). A preferred catalyst is *bis*(norbornadiene)rhodium(I) tetrafluoroborate. The amount of catalyst is a catalytic amount, typically about 1 mole % to about 5 mole % relative to the substrate.

For cyclization Step C, a typical temperature is about -10°C to about 20°C, preferably about 0°C. The pH for Step C is basic, typically, about 8 pH to about 12 pH. The Grignard reagent used in Step C can be any suitable organomagnesium compound known in the art, such as methylmagnesium chloride, ethylmagnesium chloride, isopropyl magnesium chloride, *n*-butylmagnesium chloride, methylmagnesium bromide, isopropylmagnesium bromide, cyclopropylmagnesium bromide, ethylmagnesium iodide and the like. The amount of Grignard reagent employed is a de-protonating amount which is typically in molar excess to the amount of formula (IV), e.g., about 1-5 equivalents relative to formula (IV). A preferred solvent is acetone or methylethylketone.


For Step D, a typical temperature is about 30°C to about 150°C, preferably about 60°C to about 80°C. The pH for Step D is typically about 5 pH to about 11 pH. The activator for Step D is a compound which protonates the β -lactam keto oxygen; such activators include, e.g., mild (weak) organic acids, such as branched or unbranched carboxylic acids, e.g., 2-ethylhexanoic acid, acetic acid, isobutyric acid and the like. If an aqueous alcoholic solvent is used an activator is not needed; preferred aqueous alcoholic solvents include MeOH:H₂O, EtOH:H₂O and the like. If an activator is used a preferred solvent is THF, dioxane or dimethoxyethane. If an activator is used it is used in an protonating amount which is typically about 0.1 molar equivalents to about 2 molar equivalents relative to formula (V).

For Step E, a typical temperature is about -30°C to about 50°C, preferably about 0°C to about 25°C. The pH for Step E is not critical and can vary considerably. For Step E the solvent should not be an alcoholic solvent. The formylating agent can be, e.g., HCO₂H/Ac₂O, trifluoroethylformate and the like, and is present in a formylating amount which


is typically about 1 molar equivalent to about 2 molar equivalents relative to formula (VII). A preferred solvent is EtOAc, isopropylacetate, *t*-butylacetate or THF.

To prepared the *S* enantiomer instead of the *R* enantiomer of the compounds prepared herein, the appropriate isomer of the chiral ligand will be used, e.g., (2*R*,5*R*)-Me-Duphos and (1*S*1'*S*,2*R*,2'*R*)-TangPhos. For example, Step B will comprise:

Contacting a compound of the formula (III)




with hydrogen in the presence of a chiral ligand and a catalytic amount of a hydrogenation catalyst in a suitable solvent and under conditions suitable to form a compound of the formula (IV')




All of the other steps will be the same.

Insofar as the production of starting materials is not particularly described, the compounds are known or may be prepared analogously to methods known in the art or as disclosed in the examples hereinafter.


It is further preferred that in the optically pure compound of formula (X) that R_2 , R_3 and R_5 are hydrogen and that R_4 is alkyl; such a compound has the formula (Xa)



Preferably in formula (X), R_4 is *n*-butyl, where such compound has the formula (Xb)




It is even more preferred that R_2 , R_3 and R_5 are hydrogen and that R_4 is *n*-butyl where such compound has the structure (Xc):




To prepare the starting material of the above-described process, i.e., formula (XI), the corresponding alkyl ester can be hydrolyzed as described by Stetter and Kuhlmann, *Synthesis*, pp. 29-30 (1979).


For example, in a preferred preparation, a compound of formula (XVII)



is contacted with a strong base, such as KOH, to form a compound of formula (XVIII)




followed by contacting the compound of formula (XVIII) with a reducing agent, such as LiBH_4 , NaBH_4 or borane in a suitable solvent, such as THF, DMF or diethyl ether, to form a starting material for the present process, e.g., a compound of formula (IXa)




Following the first step (Step 1), it is preferred to re-crystallize the diastereomeric salt from a suitable solvent, preferably from the same solvent system, prior to performing the second step (step 2).


A preferred process of the invention comprises resolution of a compound of formula (IXa) by contacting said compound with (*R*)- α -methylbenzylamine in a mixture of ethyl acetate and 2-propanol to form a compound of formula (IIIa)




followed by re-crystallization of the diastereomeric salt, i.e., the compound of formula (IIIa), from the same solvent, followed by contacting the compound of formula (IIIa) with a mixture of HCl (preferably about 2 *N*), and isopropyl acetate to form the compound of formula (Xc)



To form the active antibacterial agents, a third step (Step 3) is performed wherein the compound formed by the second step, i.e., the compound of formula (X), is contacted with a compound of the formula (XIX)




in the presence of a carboxy-activating agent, in a suitable solvent under conditions suitable to form a compound of the formula (XX)




followed by Step 4:

Contacting a formula (XX) with a compound of the formula (XXI)




wherein R' is alkyl or aryl and X' is halo, in the presence of a base in a suitable solvent, under conditions suitable to form a compound of the formula (XXII)




followed by Step 5:

Contacting a formula (XXII) with a base in a suitable solvent under conditions suitable to form a compound of the formula (XXIII)




followed by Step 6:

Contacting a formula (XXIII) with a compound of the formula (VI)




in a suitable solvent optionally in the presence of an activator under conditions suitable to form a compound of the formula (XXIV)




followed by Step 7:

Contacting a formula (XXIV) with a formylating agent in a suitable solvent under conditions suitable to form compound (XXV):




followed by Step 8:

converting the compound of formula (XXIV) to the compound of formula (IX) by removing the hydroxy-protecting group using conventional hydrogenation techniques known in the art, e.g., by contacting the compound of formula (XXIV) with hydrogen in the presence of a palladium catalyst, such as Pd/BaSO₄, to form the compound of formula (IX)




If desired, the (S) enantiomer can be prepared instead of the (R) enantiomer by using the (S) form of the resolving agent rather than the (R) form. Such a process comprises preparing a compound of the formula (X')




comprising Step 1':

Resolution a racemate of the compound of the formula (X'), i.e., a compound of formula (XI):



by contacting the compound of formula (X') with (S)- α -methylbenzylamine in a suitable solvent to form a (S,S)-diastomeric salt of formula (III')



followed by Step 2':

Contacting the compound of formula (XII') with a biphasic mixture of an aqueous mineral acid and an organic solvent to form the compound of formula (X'). The active (S) antibacterial agents can then be prepared using Steps 3-8 as described above.

Pressure is not known to be critical for carrying out the various steps 1 – 8 and 1' -2' of the invention. Generally, depending on the particular step, a temperature of about -10°C to about 150°C, preferably about 0°C to about 80°C, is typically employed. Typically about atmospheric pressure is used for convenience; however, variations to atmospheric pressure are not known to be detrimental. Oxygen is not known to be detrimental to the process, therefore for convenience, the various steps can be performed under ambient air, although an inert atmosphere, such as nitrogen or argon, can be used if desired. For convenience,

equimolar amounts of reactants are typically used; however, molar ratios can vary from about 1-2 equivalents, relative to the other reactant. The pH for most steps is typically about 2 pH to about 12 pH, although, as mentioned below, the pH for Step 2 must be very acidic. The solvent to be used for the various steps will depend on the nature of the reactants and other conditions and can be, e.g., ethyl acetate, isopropyl acetate, toluene, dichloromethane, dioxane, methylene chloride, toluene, acetone, methylethylketone, THF, DMF, alcohols and the like; however, the solvents for Steps 1 and 2 are listed below.

For Step 1, a typical temperature is about 10°C to about 90°C. Preferably in Step 1, the reaction mixture is initially heated to about 50°C to about 90°C, and then cooled to crystallize the desired compound, e.g., at a temperature of about 10°C to about 40°C. The amount of resolving agent, i.e., (*R*)- α -methylbenzylamine, employed is typically about 0.7 molar equivalents to about 1.5 molar equivalents relative to formula (XI). The solvent for Step 1 is a mixture of an ester or an alkyl nitrile and an alcohol. Examples of esters include, e.g., alkyl acetates, such as isopropyl acetate, *t*-butyl acetate, ethyl acetate and the like. Examples of alkyl nitriles include, e.g., acetonitrile and the like. Examples of alcohols include methanol, ethanol, isopropanol and the like. The ratio of ester or alkyl nitrile to alcohol can vary from about 90:10 to about 10:90, preferably about 75:25 to about 25:75, and most preferably about 50:50, the preceding ratios being based on volume:volume. The most preferred solvent is a mixture of ethyl acetate:2-propanol (50:50, vol:vol).

For Step 2, a typical temperature is about 10°C to about 30°C, preferably about 20°C to about 25°C. Due to the presence of the acid, the pH for Step 2 is acidic and is typically about a pH of 1 or less. The solvent for step 2 is a mixture of an aqueous mineral acid and an organic solvent which forms a biphasic solvent comprising an aqueous and organic phases. The ratio (volume:volume) of aqueous mineral acid:organic solvent can vary widely, e.g., 90:10-10:90, more typically 60:40-40:60. The desired compound of formula (X) can be recovered from the organic phase using conventional purification and/or separation techniques known in the art such as distillation, filtration and the like. To increase yield, multiple extractions from the aqueous phase can be performed with the organic layers combined and then washed with an aqueous inorganic salt solution, such as a 10-40% by weight aqueous solution of sodium chloride. Strong mineral acids are typically used for Step 2, e.g., HCl, H₂SO₄ and the like. The strength of the acid is strong enough for forming the desired compound, typically about 1 N to about 6 N, with about 2 N being preferred. The

organic solvent can be ethyl acetate, isopropyl acetate, toluene, dichloromethane dioxane, methylene chloride, toluene, acetone, methylethylketone, THF, DMF and the like.


In U.S. Serial No. 10/171,706, General Procedure A describes forming the compound of formula (XIII) by treatment of the compound of formula (XIV) with LiOH and H₂O₂. Another aspect of present process eliminates the need for using H₂O₂, thereby resulting in a process that is much safer, particularly upon scale-up.

In Step i, the alkoxide of p-methoxybenzyl alcohol can be formed *in situ* by contacting p-methoxybenzyl alcohol with an organic base such as LiHMDS, NaHMDS, and the like. The solvent for Step i can be, for example, diethyl ether, DMF, NMP, THF and the like. The temperature for Step i is not known to be critical and can vary from about 10°C to about 40°C and, for convenience, is typically preferred at RT, e.g., about 20°C to about 25°C.


For Step ii, the strong organic acid can be formic acid, p-toluenesulfonic acid, and the like. The acid typically solubilizes the compound of formula (XV), and therefore serves as the solvent for the reaction. The amount of acid is, therefore sufficient to solubilize and deprotect the compound of formula (XV). The temperature for Step ii is not known to be critical and can vary from about 10°C to about 40°C and, for convenience, is typically preferred at RT, e.g., about 20°C to about 25°C.

For both Steps i and ii, the desired products can be purified and concentrated using conventional techniques known in the art. For example, a mixture of ethyl acetate and aqueous acid or base can be added to the reaction mixture to form a biphasic solution wherein the desired product will be in the organic phase. After separation of the organic phase, it can, if desired, be subject to multiple extractions with the same or different solutions. Typical acids for this use are strong mineral acids such as HCl, H₂SO₄, and the like, and typical bases are sodium carbonate, and the like. Removal of the solvent can be accomplished using conventional techniques, e.g., distillation under reduced pressure. Further purification of the desired product can also be preformed, e.g., using chromatography such as flash chromatography, HPLC, and the like.

Compounds of formula (XIII) can be converted to active anti-bacterial compounds of formula (IX), by contacting the compounds of formula (XIII) with a compound of formula (VI')




in the presence of hydrogen gas and a palladium on carbon catalyst in a suitable solvent to form a compound of formula (XXVII)



Insofar as the production of starting materials is not particularly described, the compounds are known or may be prepared analogously to methods known in the art or as disclosed in the examples hereinafter. In U.S. Serial No. 10/171,706, General Procedure A describes forming the compound of formula XXVII.

Furthermore, another aspect of the present invention provides a novel process for preparing active anti-bacterial compounds of formula (IX) by treatment the compounds of formula (VIII) with hydrogen at sub-atmospheric partial pressures in the presence of a palladium catalyst in ethanol. The present process minimizes production of by-product, thereby resulting in a process that is environmentally benign. The reaction may be carried out by sparging a gaseous mixture of hydrogen and nitrogen at 1 atm total pressure in a reaction mixture containing compound of formula (VIII), ethanol and a palladium catalyst, e.g., palladium on carbon. The desired hydrogen partial pressure is attained by varying the relative flow rate of nitrogen and hydrogen. A reasonable reaction time is required, i.e., the reaction is allowed to proceed until the desired product is formed.


More specifically, another aspect of the present invention is directed to a process for preparing a compound of formula (IX)



wherein

X is $-\text{CH}_2-$, $-\text{S}-$, $-\text{CH}(\text{OH})-$, $-\text{CH}(\text{OR})-$, $-\text{CH}(\text{SH})-$, $-\text{CH}(\text{SR})-$, $-\text{CF}_2-$, $-\text{C}=\text{N}(\text{OR})-$ or $-\text{CH}(\text{F})-$;


R_1 is aryl or heteroaryl, preferably



each of R_2 , R_3 , R_4 and R_5 independently is hydrogen or alkyl, or (R_2 or R_3) collectively form a C_4C_7 cycloalkyl, preferably R_2 , R_3 , R_5 are hydrogen and R_4 is n-butyl; n is 0-3, preferably 1.

Comprising a step :

Converting the compound of formula (XXV)



wherein

Y is a hydroxy-protecting group, preferably benzyl,

to the compound of formula (IX) by removing the hydroxyl-protecting group by contacting the compound of formula (XXV) with molecular hydrogen at hydrogen partial pressures below 1 atm, preferably about 0.1 atm to about 0.24atm , while maintaining a total pressure of about 1atm in the presence of a palladium catalyst, such as 5% Pd/C, in a suitable solvent, preferably ethanol, at about 10 to about 30 °C , typically about 20°C.

When the debenzilation with molecular hydrogen is carried out at typical conditions (e.g., hydrogen partial pressures ≥ 1 atm) hydrogenolysis of the N-O bond in the pyridine N-oxide moiety occurs to a significant extent (i.e. yields $> 1\%$) , resulting in production of a by-product (designated as "des-oxy C10") in substantial amounts.

Because des-oxy C10 is difficult to separate from the reaction mixture by crystallization, it is highly desirable to eliminate or at least limit its production to very small amounts.

A means has been found to conduct the debenzylation very selectively, i.e., with des-oxy C10 yields of under 1%, by performing the reaction at hydrogen partial pressures below 1 atm. The examples 14 and 15 describe the experimental methods and results in detail.

Another aspect of the present invention is selective O-debenzylation in the presence of pyridine N-oxides via hydrogen transfer using formic acid/4-methylmorpholine.

The penultimate step of a synthesis of the compound of formula (IX) comprises a catalytic removal of hydroxy-protecting group by contacting the compound of formula (XXV) with hydrogen in the presence of a catalyst such as Pd/C. The compound of formula (XXV) may include a pyridine N-oxide group; when the removal of hydroxy-protecting group is carried out at typical conditions (e.g., hydrogen partial pressures at or above 1atm) hydrogenolysis of the N-O bond in the pyridine N-oxide occurs to a significant extent, resulting in production of by product in significant amounts. The latter is difficult to separate.

The deprotection can be carried out selectively via hydrogen transfer instead of using molecular hydrogen. A means has been found to conduct deprotection very selectively with a hydrogen transfer reagent comprising 4-methylmorpholine and formic acid. Preferably 1.6 eq of 4-methylmorpholine and 1.4 eq of formic acid in the presence of a catalyst. Such chemical transformation occurs at elevated temperatures, preferably reaction mixture is being heated at about 45°C for about 25±10 min.

The following abbreviations are used:

HPLC = high performance liquid chromatography

Ac=acetyl

Fmoc = 9-fluorenylmethyl-oxycarbonyl

Mom = methoxy methyl ether

Mem = methoxy ethoxy methyl ether

NPEOC = 4-nitrophenethyloxycarbonyl

NPEOM = 4-nitrophenethyloxy-methyloxycarbonyl

The following abbreviations are used:

DMAP = dimethylaminopyridine

DMF = dimethylformamide

EtOAc = ethyl acetate

EtOH = ethanol

HPLC = high performance liquid chromatography

Me = methyl

MeOH = methanol

RT = room temperature

THF = tetrahydrofuran

Nvom = nitroveratryl oxymethyl ether

Ph = phenyl

NMP = N-methylpyrrolidone

DABCO = 1,4-diazabicyclo[2.2.2]octane

psi = pounds per square inch

TBDMS = *t*-butyldimethylsilyl

TMSCl = trimethylsilyl chloride

aq. = aqueous

Et = ethyl

iPr = isopropyl

Bn = benzyl

DABCO = 1,4-diazabicyclo[2.2.2]octane

The following examples are to illustrate the invention but should not be interpreted as a limitation thereon.

Example 1. 3-Hydroxy-2-methylenehexanoic acid methyl ester:

A mixture of butanol (72.11 g, 1,000 mmol), methyl acrylate (129.14 g, 1,500 mmol) and DABCO (22.44 g, 200 mmol) is allowed to react at room temperature under N₂ for 7 days. The reaction mixture is concentrated on Rotavap under reduced pressure (20 mbar) until no further solvent distills. The residue colorless liquid is dissolved in toluene (800 mL) and washed sequentially with 2 N HCl acid (250 mL), water (250 mL), saturated aq. sodium bicarbonate solution (120 mL) and water (150 mL). The toluene layer is concentrated on Rotavap under reduced pressure (20 mbar) until no further solvent distills to afford 3-hydroxy-2-methylenehexanoic acid methyl ester (96.7 g, yield: 61.1%) as a colorless liquid.

Example 2. 3-Acetoxy-2-methylenehexanoic acid methyl ester:

A mixture of 3-hydroxy-2-methylenehexanoic acid methyl ester (55.37 g, 350 mmol) and DMAP (4.28 g, 35 mmol) in toluene (400 mL) is cooled to 0-5°C and to it is added acetic anhydride (42.88 g, 420 mmol) dropwise in ~30 minutes while maintaining the temperature at 0-5°C. The resulting solution is allowed to warm to room temperature in 1 hour. After stirring for 3 hours at RT, the reaction mixture is cooled to 0-5°C and to it is added 1 N HCl acid (80 mL), in 20 minutes. The organic layer is separated and washed sequentially with water (80 mL), saturated aqueous sodium bicarbonate solution (2 x 80 mL) and water (80 mL). The organic layer is concentrated on Rotavap under reduced pressure (20 mbar) until

no further solvent distills to afford 3-acetoxy-2-methylenehexanoic acid methyl ester (68.3 g, yield: 97.5%) as a colorless liquid.

Example 3. 2-[[[(Phenylmethoxy)amino]methyl]-2-hexenoic acid methyl ester:

A mixture of 3-acetoxy-2-methylenehexanoic acid methyl ester (4.00 g, 20 mmol) and O-benzylhydroxylamine (7.39 g, 60 mmol) in THF (30 mL) is allowed to react at RT under N₂ for 2 days. The reaction mixture is concentrated on Rotavap under reduced pressure (20 mbar) until no further solvent distills. The residue liquid is dissolved in ethyl acetate (75 mL) and washed with saturated aqueous sodium bicarbonate solution (50 mL). The ethyl acetate layer is concentrated on Rotavap under reduced pressure (20 mbar) until no further solvent distills to afford a colorless liquid (11.2 g).

The crude material is chromatographed (silica gel, 5% ethyl acetate in heptane) to afford a ~1:1 mixture of (*E*) and (*Z*)-2-[[[(phenylmethoxy)amino]methyl]-2-hexenoic acid methyl ester (4.01 g, yield: 76%) as a colorless liquid.

Example 4. 2-[[[(Phenylmethoxy)amino]methyl]-(2*S*)-hexanoic acid methyl ester:

A ~1:1 mixture of (*E*) and (*Z*)-2-[[[(phenylmethoxy)amino]methyl]-2-hexenoic acid methyl ester (3.95 g, 15 mmol), *bis*(norbornadiene)rhodium(I) tetrafluoroborate (56.1 mg, 0.15 mmol) and (1*S*,1'*S*,2*R*,2'*R*)-TangPhos (47.3 mg, 0.165 mmol) in de-oxygenated methanol (90 mL) in a Parr bottle is hydrogenated under H₂ (45-55 psi) at RT for 24 hours. The reaction mixture is concentrated on Rotavap under reduced pressure (20 mbar) until no further solvent distills. The residue liquid is dissolved in a mixture of ethyl acetate/heptane (50/50, 10 mL) and filtered through a silica gel pad (~12 g). The silica gel pad is rinsed with a mixture of ethyl acetate/heptane (50/50, 200 mL). The filtrates are combined and concentrated on Rotavap under reduced pressure (20 mbar) until no further solvent distills to afford 2-[[[(phenylmethoxy)amino]methyl]-(2*S*)-hexanoic acid methyl ester (3.76 g, yield: 94%, S:R = 98.0:2.0) as a liquid.

2-[[[(Phenylmethoxy)amino]methyl]-(2*S*)-hexanoic acid methyl is also prepared using (2*R*,5*R*)-Me-Duphos (yield: 95%, R:S = 98:2).

Example 5. 2-[[[(Phenylmethoxy)amino]methyl]-(2*R*)-hexanoic acid methyl ester:

(1*R*,1'*R*,2*S*,2'*S*)-TangPhos affords 2-[[[(phenylmethoxy)amino]methyl]-(2*R*)-hexanoic acid methyl ester (yield: 96%, R:S = 98.6:1.4)

Similarly, (2*S*,5*S*)-Me-Duphos affords 2-[[[(phenylmethoxy)amino]methyl]-(2*R*)-hexanoic acid methyl ester (yield: 98%, R:S = 98.8:1.2).

Example 6. 1-Benzyloxy-(3*S*)-butyl-2-azitidinone:


To a solution of 2-[[[(phenylmethoxy)amino]methyl]-(2*S*)-hexanoic acid methyl ester (265 mg, 1.0 mmol) in tetrahydrofuran (5.0 ml) at 0°C is added dropwise, 3.0 M methylmagnesium chloride (0.76 mL, 2.30 mmol) at a rate maintaining the same internal temperature. The resulting solution is stirred for 1 hour at 0 -3 °C and the reaction is quenched by addition of pH 7 phosphate buffer (5.0 ml). Ethyl acetate (30 mL) is added, the organic layer is separated and washed with water (20 mL). The organic layer is concentrated under reduced pressure to afford the crude product as an oil which is purified by flash chromatography on silica gel to give 1-benzyloxy-(3*S*)-butyl-2-azitidinone (112 mg, 50% yield, S:R = 92.7:7.3)).

Example 7. 1-Benzyloxy-(3*R*)-butyl-2-azitidinone:

2-[[[(phenylmethoxy)amino]methyl]-(2*R*)-hexanoic acid methyl ester affords 1-benzyloxy-(3*R*)-butyl-2-azitidinone.

The examples 8, 9, 10 and 11 that follow make reference to reaction scheme1 below:

Scheme 1



Example 8 Preparation of (±)-2-butyl-3-hydroxypropionic acid (4):

A 12 L, 4-necked, round-bottomed flask, equipped with a mechanical stirrer, digital thermometer, and nitrogen inlet-outlet is charged with 2-butyl-propanedioic acid monoethyl ester (3, 450.0 g, 2.39 mol) and isopropanol (4.5 L). The solution is cooled to an internal temperature at 15-18°C and a 2 M solution of lithium borohydride (2.4 L, 4.8 mol) in tetrahydrofuran is added over a period of 1.5 hours while maintaining the internal temperature at 15-25°C. The stirring is continued for an additional 3 h. The reaction mixture is cooled to an internal temperature at 10-13°C and quenched by the addition of 2 N HCl (2.4 L) over a period of 1 hour while maintaining the internal temperature at 10-25°C. The reaction mixture is concentrated at 35-40°C (20 mbar) to collect ~7.5 L of the solvent to obtain a suspension (~1.9 kg). This suspension is diluted with water (2.0 L) and ethyl acetate (2.5 L) and the biphasic mixture is stirred for 1 hour. The organic layer is separated and the aqueous layer is extracted with ethyl acetate (2.0 L). The combined organic layers are washed with 20% aqueous solution of sodium chloride (1.0 L) and concentrated under vacuum (20 mbar) until no further solvent distills to afford crude (±)-2-butyl-3-hydroxypropionic acid (4, 349.4 g, 100%) as a colorless liquid, which is used as such in the next step.

Example 9 Resolution of (±)-2-butyl-3-hydroxypropionic acid (4):

A 5 L, 4-necked, round-bottomed flask, equipped with a mechanical stirrer, digital thermometer, reflux condenser, addition funnel with nitrogen inlet-outlet, and heating mantle is charged with (*R*)- α -methylbenzylamine (280.7 g, 2.316 mol), isopropanol (1.9 L) and ethyl acetate (1.63 L). The solution is stirred and heated to an internal temperature at 60-65°C, and a solution of (±)-2-butyl-3-hydroxypropionic acid (4, 322.5 g, 2.206 mol) in ethyl acetate (0.2 L) is added over a period of 15 min while maintaining the internal temperature at 60-70°C. The addition funnel is washed with ethyl acetate (0.2 L) and added to the mixture. The solution is cooled to 20-25°C over a period of 2 hours and the resulting suspension is stirred at the same temperature for an additional 5 hours. The solids are collected by filtration, washed with a mixture of ethyl acetate-isopropanol (2:1 v/v) in two equal portions of 0.5 L each, and dried at 50-53°C (13-49 mbar) to afford crude (*R*)-2-butyl-3-hydroxypropionic acid (*R*)- α -methylbenzylammonium salt (5, 246.3 g; 41.7%); (*R*):(*S*) = 94.1:5.9.

Crude (*R*)-2-butyl-3-hydroxypropionic acid (*R*)- α -methylbenzylammonium salt (**5**, 246.3 g) is transferred to a 5 L, 4-necked, round-bottomed flask, equipped with a mechanical stirrer, digital thermometer, reflux condenser, addition funnel with nitrogen inlet-outlet and heating mantle. Ethyl acetate (1.225 L) and isopropanol (1.225 L) are then added. The suspension is stirred and heated to an internal temperature at 70-80°C over a period of 1 hour to obtain a solution. The solution is cooled to 20-25°C over a period of 2 hours and the resulting suspension is stirred at the same temperature for an additional 5 hours. The solids are collected by filtration, washed with a mixture of ethyl acetate-isopropanol (2:1 v/v) in two equal portions of 0.4 L each, and dried at 50-53°C (13-19 mbar) to afford pure (*R*)-2-butyl-3-hydroxypropionic acid (*R*)- α -methylbenzylammonium salt (**5**, 215.6 g; 36.5%; 73.0% of theory); m.p. 145-147°C; $[\alpha]_D^{25} +8.8$ ($c = 1.0$, CH₃OH); (*R*):(*S*) = 99.3:0.7.

Example 10 (*R*)-2-Butyl-3-hydroxypropionic acid (1**):**

(*R*)-2-Butyl-3-hydroxypropionic acid (*R*)- α -methylbenzylammonium salt (**5**, 10.0 g) is dissolved in 2 N HCl (40.0 mL) and isopropyl acetate (50.0 mL) is added to the mixture. After mixing for 5 min, the organic layer is separated and the aqueous layer is extracted with isopropyl acetate (3 x 50.0 mL). The combined organic layers are washed with water (20.0 mL) and concentrated under vacuum (20 mbar) until no further solvent distills to afford (*R*)-2-butyl-3-hydroxypropionic acid (**1**, 5.4 g; 98%); oil; $[\alpha]_D^{25} +6.5$ ($c = 1.0$, CH₃OH), (*R*):(*S*) = 99.3:0.7.

Example 11 (*S*)-2-Butyl-3-hydroxypropionic acid:

(*S*)-2-Butyl-3-hydroxypropionic acid is prepared by the resolution of (\pm)-2-butyl-3-hydroxypropionic acid (**4**) with (*S*)- α -methylbenzylamine in a similar manner as described above for the (*R*)-enantiomer. (*S*)-2-butyl-3-hydroxypropionic acid (*S*)- α -methylbenzylammonium salt, yield 33.2% (66.4% of theory); m.p. 145-147°C; $[\alpha]_D^{25} -8.9$ ($c = 1.0$, CH₃OH); (*S*)-2-butyl-3-hydroxypropionic acid: yield 98%; oil; $[\alpha]_D^{25} -6.6$ ($c = 1.0$, CH₃OH); (*R*):(*S*) = 0.4:99.6.

Table 1: Resolution of 4 (1.0 g) with (*R*)- α -methylbenzylamine (1.0 equiv)

Entry	Solvent (ratio)	Solvent volume (mL/g of 4)	Enantiopurity of 5 (<i>R</i>) : (<i>S</i>)	Isolated Yield (%)
1	CH ₃ CN : CH ₃ OH (75 : 25)	13.6	85.6 : 14.4	31.0
2	EtOAc : CH ₃ OH (70 : 30)	10.0	96.0 : 4.0	26.7
3	EtOAc : acetone (70 : 30)	10.0	54.7 : 45.3	73.3
4	EtOAc : C ₂ H ₅ OH (70 : 30)	10.0	89.3 : 10.7	36.4
5	EtOAc : <i>i</i> -PrOH (50 : 50)	12.0	94.1 : 5.9	41.7
	Recrystallization	10.0	99.3 : 0.7	36.5


Example 12. Displacement of chiral auxillary with 4-methoxybenzyl alcohol:

To XIV (5.1 g, 11.6 mmol in THF (30 mL)) is added a mixture of 4-methoxybenzyl alcohol (1.93 g, 13.9 mmol), LiHMDS (1.95 g, 11.6 mmol) and tetrahydrofuran (40 mL) at 20°C slowly and dropwise. The resulting mixture is stirred for 2 hours at 22°C. Ethyl acetate (150 mL) and 1 N HCl solution (40 mL) are added to the reaction mixture and the organic layer is separated. The organic layer is washed with water (50 mL), saturated NaHCO₃ solution (50 mL) and water (50 mL). The solvent is removed under reduced pressure to afford a crude product as an oil which is purified by flash chromatography on silica gel to give the desired XV (4-methoxybenzyl ester, 2.81 g, 60% yield).

Example 13. Deprotection of 4-methoxybenzyl ester to (XIII):

A mixture of 4-methoxybenzyl ester, XV, (820 mg, 2.05 mmol) and formic acid (8 mL) is stirred at 22°C for 2 hours. The reaction mixture is concentrated under reduced pressure. Ethyl acetate (50 mL) and 1 N Na₂CO₃ solution (15 mL) are added to the resulting residue and the aqueous layer is separated. The aqueous layer is acidified with 2 N HCl solution (10 mL) and extracted with ethyl acetate (2 x 30 mL). The organic layer is washed with water (20 mL). The solvent is removed under reduced pressure to afford a crude product as an oil which is purified by flash chromatography on silica gel to give the XIII (420 mg, 74% yield).

The examples 14 and 15 that follow make reference to reaction scheme below:

**Example 14: Debenzylation at hydrogen pressure of 0.24 atm:**


A means to operate at subatmospheric H₂ partial pressures while maintaining a total pressure of 1 atmospheric was achieved (thus obviating solvent evaporation and leaks) by performing the reaction using H₂ diluted with N₂). The apparatus comprises two calibrated

mass flow controllers, one for N_2 and the other for H_2 , which allow for a controlled flow rate of each gas based on an inputted set point. By varying the relative flow rates of the two gases, any H_2 partial pressure can be achieved. A 250-mL jacketed vessel equipped with a gassing agitator is charged with 8 g of C9, 62 g (~80 mL) of 200-proof ethanol, and 1.3 g of 5% Pd/C catalyst (Degussa, E1070 NO 5% Pd, water content 66.2 of wt %, Lot # 6JLG30), or 0.44 g of catalyst on a dry basis. The headspace is purged of air by flowing N_2 through both mass flow controllers at about 30 cm³/min. The reactor is kept open to the atmospheric, giving a pressure of 1 atm in the vessel. The reaction is started by setting flow rates of 28 and 9 cm³/min, respectively, on the N_2 and H_2 mass flow controllers, giving a H_2 partial pressure of 0.24 atm. A 700 rpm agitation rate is used, and the reaction temperature is 20°C. The lower hydrogen concentration in the liquid-phase gives a slower reaction, with the time required for 100% C9 conversion being about 3 h vs. 1.7 h for the 1-atm H_2 partial pressure case. A significant des-oxy C10 selectivity advantage is observed at 0.24 H_2 partial pressure. For example, a 0.99% des-oxy C10 yield is obtained at 97.6% C9 conversion, giving a selectivity of 1.01% vs. a des-oxy C10 yield of 6.07% at 99.8% C9 conversion, giving a selectivity of 6.1%, in the 1-atm case.

Example 15: Debenzylation at a hydrogen partial pressures of 0.1 atm:

A 250-mL jacketed vessel equipped with a gassing agitator is charged with 8 g of C9, 62 g (~80 mL) of 200-proof ethanol, and 1.4 g of 5% Pd/C catalyst (Degussa, E1070 NO 5% Pd, water content 68.05 of wt %, Lot # CC1-2215), or 0.45 g of catalyst on a dry basis. The headspace is purged of air by flowing N_2 through both mass flow controllers at about 30 cm³/min. The reactor is kept open to the atmospheric, giving a pressure of 1 atm in the vessel. The reaction is started by setting flow rates of 28 and 3 cm³/min, respectively, on the N_2 and H_2 mass flow controllers, giving a H_2 partial pressure of 0.1 atm. A slower reaction is obtained relative to the 0.24 H_2 partial pressure case (4.5 vs. 3 h), but the reaction is not unreasonably long for a production process. Even more favorable des-oxy C10 selectivities are obtained at 0.1 atm H_2 partial pressure, viz., 0.78% des-oxy C10 yield at 99.8% C9 conversion, giving a des-oxy C10 selectivity of 0.78% vs. a 0.99% des-oxy C10 yield at 97.6% C9 conversion, giving a selectivity of 1.01%, for the 0.24-atm H_2 partial pressure case.

Example 16 makes reference to reaction scheme below:




Example 16


A jacketed vessel is charged with 169.85 mmol solution of C9 in ethanol, 27.497 g of 4-methylmorpholine and 138.0 g of 200-proof ethanol. After stirring reaction mixture at about 22°C 10.845 g of formic acid is added at a rate to maintain 22°C following by addition of 69.0g of 200-proof ethanol. 8.016 g of 10%Pd/C are added to the reaction following by addition of 44.28 g of 200-proof ethanol. Mixture is heated to about 45°C for a period 25±10min. Batch is held at this temperature for 2-3 hours. Filtered and twice washed with ethanol yielding C10.

WHAT IS CLAIMED IS:

1. A process comprising contacting the compound of formula (III)



with hydrogen in the presence of a chiral ligand and a catalytic amount of a hydrogenation catalyst in a suitable solvent and under conditions suitable to form a compound of the formula (IV)



wherein R is alkyl;


each of R₂, R₃, and R₁₀ independently is hydrogen or alkyl, or (R₂ or R₃) collectively form a C₄-C₇cycloalkyl

and Y is a hydroxyl protecting group.


2. The process of Claim 1 wherein the chiral ligand is (2*S*,5*S*)-Me-Duphos, or (1*R*,1'*R*,2*S*,2'*S*)-TangPhos and the hydrogenation catalyst is a metal catalyst containing rhodium (Rh I) or ruthenium (Ru II).
3. The process of Claim 2 wherein the temperature is about 10°C to about 50°C, the solvent is dioxane, methylene chloride, dichloromethane, toluene, acetone, methylethylketone, THF, isopropyl acetate, DMF, or an alcohol, the hydrogen is in the form of hydrogen gas, the pressure is about 40 psi to about 100 psi, the amount of chiral ligand is about 1 mole % to about 15 mole % relative to the substrate, the hydrogenation catalyst is *bis*(norbornadiene)rhodium(I) tetrafluoroborate, and the amount of catalyst is about 1 mole % to about 5 mole % relative to the substrate.

4. The process of Claim 1 wherein wherein R is methyl; R₁₀ is *n*-propyl, and each of R₂, and R₃, is hydrogen.


5. A process comprising contacting a compound of the formula (III)



with hydrogen in the presence of (2*R*,5*R*)-Me-Duphos or (1*S*1'*S*,2*R*,2'*R*)-TangPhos and a catalytic amount of a hydrogenation catalyst in a suitable solvent and under conditions suitable to form a compound of the formula (IV')




6. A process for preparing a compound of formula (VIII)




comprising Step A:


contacting a compound of formula (I)



with a compound of the formula (II)




in a suitable solvent under conditions suitable to form a compound of the formula (III)




followed by asymmetric hydrogenation Step B:

contacting the compound of formula (III) with hydrogen in the presence of a chiral ligand and a catalytic amount of a hydrogenation catalyst in a suitable solvent and under conditions suitable to form a compound of the formula (IV)




followed by Step C:

contacting the compound of formula (IV) with a base such as a Grignard reagent in a suitable solvent under conditions suitable to form a compound of the formula (V)




followed by Step D:

contacting the compound of formula (V) with a compound of the formula (VI)



in a suitable solvent, optionally in the presence of an activator under conditions suitable to form a compound of the formula (VII)



followed by Step E:

contacting the compound of formula (VII) with a formylating agent in a suitable solvent under conditions suitable to form the compound of formula (VIII):

wherein

X is $-\text{CH}_2-$, $-\text{S}-$, $-\text{CH}(\text{OH})-$, $-\text{CH}(\text{OR})-$, $-\text{CH}(\text{SH})-$, $-\text{CH}(\text{SR})-$, $-\text{CF}_2-$, $-\text{C}=\text{N}(\text{OR})-$ or $-\text{CH}(\text{F})-$;

Y is a hydroxyl-protecting group;

R is alkyl;


R₁ is aryl or heteroaryl;

Ac is acetyl;

each of R₂, R₃, and R₁₀ independently is hydrogen or alkyl, or (R₂ or R₃) collectively form a C₄-C₇-cycloalkyl; and

n is 0-3, provided that when n is 0, X is $-\text{CH}_2-$.

7. The process of Claim 6 wherein R₁ is a heteroaryl of formula (II.1)



wherein

R₆, R₇ and R₉ are hydrogen; and

R₈ is methyl or trifluoromethyl; or

R₆, R₇ and R₈ are hydrogen; and

R₉ is fluoro; or

R₆, R₈ and R₉ are hydrogen; and

R₇ is ethyl or methoxy; or

R₇, R₈ and R₉ are hydrogen; and

R₆ is hydroxy; or

R_7 and R_8 are hydrogen;

R_6 is methoxy; and

R_9 is methyl;


X is $-\text{CH}_2-$, $-\text{CH}(\text{OH})-$, $-\text{CH}(\text{OR})-$, $-\text{CF}_2-$ or $-\text{CH}(\text{F})-$, preferably X is $-\text{CH}_2-$;

R_2 , R_3 , R_5 are hydrogen;

R_4 is $\text{C}_1\text{-C}_6$ alkyl; and

n is 1.

8. The process of Claim 6 wherein R_1 is a heteroaryl of formula (III.1)



wherein

R_6 , R_7 and R_9 are hydrogen; and

R_8 is fluoro or trifluoromethyl; or

R_6 , R_8 and R_9 are hydrogen; and

R_7 is ethyl;

X is $-\text{CH}_2-$, $-\text{CH}(\text{OH})-$, $-\text{CH}(\text{OR})-$, $-\text{CF}_2-$ or $-\text{CH}(\text{F})-$, preferably X is $-\text{CH}_2-$;

R_2 , R_3 , R_5 are hydrogen;

R_{10} is $\text{C}_1\text{-C}_5$ alkyl; and

n is 1.

9. The process of Claim 7 wherein

R_6 , R_7 and R_9 are hydrogen, R_8 is fluoro, X is $-\text{CH}_2-$; and R_{10} is *n*-propyl.

10. The process of Claim 6 wherein

for Step A the temperature is about 10°C to about 50°C and the solvent is THF, DMF, or NMP,

for Step B, the temperature is about 10°C to about 50°C , the solvent is dioxane, methylene chloride, dichloromethane, toluene, acetone, methylethylketone, THF, isopropyl acetate, DMF, or an alcohols, the hydrogen is in the form of hydrogen gas, the pressure is about 40 psi to about 100 psi, the chiral ligand is (2*S*,5*S*)-Me-Duphos, or (1*R*,1'*R*,2*S*,2'*S*)-TangPhos, the amount of chiral ligand is about 1 mole % to about 15 mole % relative to the


substrate, the hydrogenation catalyst is a transition metal complex containing rhodium (Rh I) or ruthenium (Ru II), the amount of catalyst is about 1 mole % to about 5 mole % relative to the substrate.

for Step C the temperature is about -10°C to about 20°C , the pH for Step C is about 8 pH to about 12 pH, the base is a Grignard reagent, the amount of Grignard reagent is about 1-5 equivalents relative to formula (IV), the solvent is acetone or methylethylketone,


for Step D the temperature is about 30°C to about 150°C , the pH for Step D is about 5 pH to about 11 pH, the activator, if present, is a branched or unbranched carboxylic acid, the solvent is an aqueous alcoholic solvent is selected from $\text{MeOH}\cdot\text{H}_2\text{O}$, $\text{EtOH}\cdot\text{H}_2\text{O}$, or the solvent is THF, dioxane or dimethoxyethane,

for Step E the temperature is about -30°C to about 50°C , the formylating agent is $\text{HCO}_2\text{H}/\text{Ac}_2\text{O}$, or trifluoroethylformate and the solvent is EtOAc, isopropylacetate, *t*-butylacetate or THF.

11. The process of Claim 6 followed by the additional step of contacting the compound of formula (VIII) with hydrogen in the presence of a palladium catalyst to form a compound of formula (IX)




12. A process for preparing a compound of the formula (X)




comprising Step 1:

resolution of the compound of formula (XI):



by contacting the compound of formula (XI) with (*R*)- α -methylbenzylamine in a suitable solvent to form the (*R,R*)-diastomeric salt of formula (XII)



followed by Step 2:

contacting the compound of formula (XII) with a biphasic mixture of an aqueous mineral acid and an organic solvent to form the compound of formula (I),

wherein

each of R_2 , R_3 , R_4 and R_5 is, independently, hydrogen or alkyl; or R_2 and R_3 , collectively, form a C_4 - C_7 cycloalkyl, provided that R_4 and R_5 are different.

13. The process of Claim 12 wherein R_2 , R_3 and R_5 are hydrogen and R_4 is alkyl
14. The process of Claim 13 wherein R_4 is *n*-butyl.
15. The process of Claim 12 wherein

for Step 1 the temperature is about 10°C to about 90°C, the amount of (*R*)- α -methylbenzylamine, is about 0.7 molar equivalents to about 1.5 molar equivalents relative to formula (II), the solvent is a mixture of an ester or an alkyl nitrile and an alcohol, the ratio of ester or alkyl nitrile to alcohol is about 90:10 to about 10:90 (vol:vol),

for Step 2 the temperature is about 10°C to about 30°C, the pH is about 1 or less, the solvent is a biphasic mixture of an aqueous mineral acid and an organic solvent, and the ratio of aqueous mineral acid:organic solvent is about 90:10-10:90 (vol:vol)

16. The process of Claim 15 wherein

for Step 1 the reaction mixture is initially heated to about 50°C to about 90°C, and then cooled at a temperature of about 10°C to about 40°C to crystallize the desired compound, the solvent for Step 1 is a mixture of an ester or an alkyl nitrile and an alcohol, wherein the ester is selected from isopropyl acetate, t-butyl acetate, and ethyl acetate, the alkyl nitrile is acetonitrile, the alcohol is selected from include methanol, ethanol, and isopropanol, the ratio of ester or alkyl nitrile to alcohol is about 75:25 to about 25:75.


for Step 2 the temperature is about 20°C to about 25°C, and the ratio of aqueous mineral acid:organic solvent is about 60:40-40:60, the mineral acid is HCl or H₂SO₄, and the solvent is ethyl acetate, isopropyl acetate, toluene, dichloromethane dioxane, methylene chloride, toluene, acetone, methylethylketone, THF, or DMF.

17. The process of Claim 16 wherein

for Step 1, the solvent is a mixture of ethyl acetate:2-propanol (50:50, vol:vol),


for Step 2 the solvent is a mixture of 2 N HCl and ethyl acetate.

18. A process for preparing a compound of the formula (X')




comprising Step 1':

resolution of the compound of formula (XI):



by contacting the compound of formula (XI') with (S)- α -methylbenzylamine in a suitable solvent to form a (S,S)-diastomeric salt of formula (XII')




followed by Step 2:

contacting the compound of formula (XII') with a biphasic mixture of an aqueous mineral acid and an organic solvent to form the compound of formula (X').


19. The process of Claim 12 followed by additional steps:

Step 3

contacting the compound of formula (X) with a compound of the formula (II)




in the presence of a carboxy-activating agent, in a suitable solvent under conditions suitable to form a compound of the formula (XX)




followed by Step 4:

contacting a formula (XIII) with a compound of the formula (XXI)




wherein R' is alkyl or aryl and X' is halo, in the presence of a base in a suitable solvent, under conditions suitable to form a compound of the formula (XXII)




followed by Step 5:

contacting a formula (XXII) with a base in a suitable solvent under conditions suitable to form a compound of the formula (XXIII)




followed by Step 6:

contacting a formula (V) with a compound of the formula (VI)




in a suitable solvent optionally in the presence of an activator under conditions suitable to form a compound of the formula (XXV)




followed by Step 7:

contacting a formula (XXIV) with a formylating agent in a suitable solvent under conditions suitable to form compound (XXV):




20. A process for preparing a compound of the formula (XIII)




comprising Step i:

Contacting a compound of the formula (XIV)



with an alkoxide of p-methoxybenzyl alcohol, in a suitable solvent under conditions to form a compound of formula (XV)



followed by deprotection Step ii:

contacting the compound of formula (XV) with a strong organic acid in a suitable solvent under conditions to form the compound of formula (XIII),


wherein

R₄ is alkyl;


Bn is benzyl; and

Me is methyl.

21. The process of Claim 20 wherein R₄ is a C₁-C₆alkyl.
22. The process of Claim 20 wherein R₄ is *n*-butyl.
23. The process of Claim 20 wherein the alkoxide of p-methoxybenzyl alcohol is formed in situ by contacting p-methoxybenzyl alcohol with LiHMDS or NaHMDS..
24. The process of Claim 20 wherein the solvent for Step i is diethyl ether, DMF, NMP, or THF and the temperature for Step i is about 10°C to about 40°C.
25. The process of Claim 20 wherein the strong organic acid is formic acid or p-toluenesulfonic acid, and the temperature for Step ii is about 10°C.
26. The process of Claim 20 followed by the additional step of contacting the compound of formula (XIII) with a compound of formula (VI')



in the presence of hydrogen gas and a palladium on carbon catalyst in a suitable solvent to form a compound of formula (XXVII)



wherein

R_4 is as defined above;


X is $-CH_2-$, $-S-$, $-CH(OH)-$, $-CH(OR')-$, $-CH(SH)-$, $-CH(SR')-$, $-CF_2-$, $-C=N(OR')-$ or $-CH(F)-$;

R' is alkyl;

R_1 is heteroaryl or aryl; and

n is 0-3, provided that when n is 0, X is $-CH_2-$.

27. The process of Claim 26 wherein R_1 is a heteroaryl of formula (II.1)



wherein

R_6 , R_7 and R_9 are hydrogen; and

R_8 is methyl or trifluoromethyl; or

R_6 , R_7 and R_8 are hydrogen; and

R₉ is fluoro; or

R₆, R₈ and R₉ are hydrogen; and

R₇ is ethyl or methoxy; or

R₇, R₈ and R₉ are hydrogen; and

R₆ is hydroxy; or

R₇ and R₈ are hydrogen;

R₆ is methoxy; and


R₉ is methyl;

X is -CH₂-, -CH(OH)-, -CH(OR)-, -CF₂- or -CH(F)-;

R is C₁-C₆alkyl; and

n is 1.

28. The process of Claim 26 wherein R₁ is a heteroaryl of formula (III.1)



(III.1)

wherein

R₆, R₇ and R₉ are hydrogen; and

R₈ is fluoro or trifluoromethyl; or

R₆, R₈ and R₉ are hydrogen; and

R₇ is ethyl; preferably R₁ is a heteroaryl of formula (II.1),

wherein

R_6 , R_8 and R_9 are hydrogen; and

R_7 is ethyl or a heteroaryl of formula (III.1),

wherein

R_6 , R_7 and R_9 are hydrogen; and

R_8 is fluoro.


X is $-CH_2-$, $-CH(OH)-$, $-CH(OR)-$, $-CF_2-$ or $-CH(F)-$;

R is C_1 - C_6 alkyl; and

n is 1.

29. The process of claim 29 wherein R_4 is *n*-butyl, X is $-CH_2-$, R_6 , R_7 , and R_9 are hydrogen; and R_8 is fluoro.


30. The process for preparing a compound of formula (IX)



wherein

X is $-CH_2-$, $-S-$, $-CH(OH)-$, $-CH(OR)-$, $-CH(SH)-$, $-CH(SR)-$, $-CF_2-$, $-C=N(OR)-$ or $-CH(F)-$;

R_1 is




each of R_2 , R_3 , R_4 and R_5 independently is hydrogen or alkyl, or (R_2 or R_3) collectively form a C_4 - C_7 cycloalkyl, preferably R_2 , R_3 , R_5 are hydrogen and R_4 is *n*-butyl;

n is 0-3,

comprising:

converting the compound of formula (XXV)



wherein


Y is a hydroxy-protecting group,

to the compound of formula (IX) by removing the hydroxyl-protecting group by contacting the compound of formula (XXV) with molecular hydrogen at hydrogen partial pressures about less than 1atm in the presence of a palladium catalyst in a suitable solvent.

31. The process of claim 30 wherein the partial hydrogen pressure is about 0.24atm, the solvent is ethanol and the catalyst is 5%Pd/C, about 1atm total pressure is achieved by use of nitrogen and the reaction temperature is 20°C.

32. The process of claim 31 wherein the partial hydrogen pressure is about 0.1 atm.


33. The process for preparing a compound of formula (IX)



wherein

X is -CH₂-, -S-, -CH(OH)-, -CH(OR)-, -CH(SH)-, -CH(SR)-, -CF₂-, -C=N(OR)- or -CH(F)-;

R₁ is




each of R_2 , R_3 , R_4 and R_5 independently is hydrogen or alkyl, or (R_2 or R_3) collectively form a C_4C_7 cycloalkyl, preferably R_2 , R_3 , R_5 are hydrogen and R_4 is n-butyl;

n is 0-3,

comprising:

converting the compound of formula (XXV)



wherein

Y is a hydroxyl-protecting group.

to the compound of formula (IX) by removing the hydroxyl-protecting group by contacting the compound of formula (XXV) with a hydrogen transfer reagent comprising 4-methylmorpholine and formic acid in the presence of a palladium catalyst, in a suitable solvent.

34. The process of claim 33 wherein hydrogen transfer reagent comprises about 1.6 eq of 4-methylmorpholine and about 1.4 eq of formic acid.
35. The process of claim 33 wherein reaction mixture is heated to about 45°C for about 25 ± 10 min.

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
10 September 2004 (10.09.2004)

PCT

(10) International Publication Number
WO 2004/076053 A3

(51) International Patent Classification⁷: **C07C 239/20**,
C07D 401/12, C07B 53/00, C07C 259/06, A61K 31/44,
A61P 31/04

(74) Agents: SAVITSKY, Thomas et al.; Novartis AG, Corporate Intellectual Property, CH-4002 Basel (CH).

(21) International Application Number:
PCT/US2004/005159

(22) International Filing Date: 20 February 2004 (20.02.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/449,015 21 February 2003 (21.02.2003) US
60/449,016 21 February 2003 (21.02.2003) US
60/449,017 21 February 2003 (21.02.2003) US

(71) Applicant (for all designated States except AT, US): NO-VARTIS AG [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).

(71) Applicant (for AT only): NOVARTIS PHARMA GMBH [AT/AT]; Brunner Strasse 59, 1230 Vienna (AT).

(72) Inventors; and

(75) Inventors/Applicants (for US only): PRASHAD, Mahavir [US/US]; 27 Davenport Road, Montville, NJ 07045 (US). KIM, Hang-Yong [KR/US]; 2104 Harvest Court, Whippany, NJ 07981 (US). HU, Bin [CN/US]; 1275 Rock Avenue, D-6, North Plainfield, NJ 07600 (US). SLADE, Joel [US/US]; 14 Theresa Drive, Flanders, NJ 07836 (US). KAPA, Prasad, Koteswara [US/US]; 4 Faber Road, Parsippany, NJ 07054 (US). GIRGIS, Michael, John [US/US]; 16 Skyline Drive, Montville, NJ 07045 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).


Published:

— with international search report
— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(88) Date of publication of the international search report:
2 December 2004

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: CHEMICAL PROCESS FOR THE PREPARATION OF INTERMEDIATES TO OBTAIN N-FORMYL HYDROXY-LAMINE COMPOUNDS



(I)

(57) Abstract: Improved processes for preparing intermediates useful for preparing antibacterial N-[1-oxo-2-alkyl-3-(N-hydroxy-formamido)-propyl]-(carbonylamino-aryl or -heteroaryl)-azacyclo4-7alkanes or thiazacyclo4-7alkanes, which have one or more of the following features: (1) make use of a particular β -lactam intermediate; (2) which make use of a particular resolving agents, enantiomerically pure substituted propionic acids, especially (R)-2-butyl-3-hydroxy-propionic acid; (3) which avoid the use of hydrogen peroxide; and (4) which facilitate selective debenzoylation reducing production of waste by-products. See Formula (I).

BEST AVAILABLE COPY

WO 2004/076053 A3

INTERNATIONAL SEARCH REPORT

International Application No.
PCT/US2004/005159

Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

1-11

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

Form PCT/ISA/210 (continuation of first sheet (2)) (January 2004)

BEST AVAILABLE COPY

INTERNATIONAL SEARCH REPORT

International Application No.
PCT/US2004/005159

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C07C239/20 C07D401/12 C07B53/00 C07C259/06 A61K31/44
A61P31/04

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 C07C A61K C07B C07D A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data, PAJ, BEILSTEIN Data, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 02/102790 A1 (VERICOR, INC., USA; NOVARTIS AG) 27 December 2002 (2002-12-27) claims examples Schemes, p.15, p.18 abstract	1-11
P,A	US 6 576 772 B1 (ZHANG XUMU) 10 June 2003 (2003-06-10) claims tables	1-11
A	US 6 423 690 B1 (DAVIES STEPHEN JOHN ET AL) 23 July 2002 (2002-07-23) claims column 29 abstract	1-11

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another claim or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"Z" document member of the same patent family

Date of the actual completion of the international search

21 July 2004

Date of mailing of the international search report

1. 10. 04

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 851 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Stix-Malaun, E

Form PCT/ISA/210 (second sheet) (January 2004)

BEST AVAILABLE COPY

INTERNATIONAL SEARCH REPORT

International Application No. PCT/ US2004/ 005159

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 1-11

Preparation of intermediates of formula (IV) for the preparation of antibacterial compounds.

2. claims: 12-19

Preparation of intermediates of formulae (X) and (X') for the preparation of antibacterial compounds.

3. claims: 20-29

Preparation of intermediates of formula (XIII) for the preparation of antibacterial compounds.

4. claims: 30-32

Preparation of compounds of formula (IX) from compounds of formula (XXV).

5. claims: 33-35

Preparation of compounds of formula (IX) from compounds of formula (XXV).

INTERNATIONAL SEARCH REPORT

International Application No.
PCT/US2004/005159

Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

1-11

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

Internal Publication No

PCT/04/005159

Patent document cited in search report		Publication date		Patent family member(s)	Publication date
WO 02102790	A1	27-12-2002	BR	0210377 A	10-08-2004
			CA	2448526 A1	27-12-2002
			CZ	20033388 A3	17-03-2004
			EP	1401828 A1	31-03-2004
			HU	0400208 A2	28-06-2004
			SK	15242003 A3	07-07-2004
			US	2003045479 A1	06-03-2003
			US	2003210101 A1	13-11-2003

US 6576772	B1	10-06-2003	US	2003232991 A1	18-12-2003
			US	2004167339 A1	26-08-2004
			AU	1481301 A	06-06-2001
			CA	2390998 A1	17-05-2001
			EP	1228034 A2	07-08-2002
			WO	0134612 A2	17-05-2001

US 6423690	B1	23-07-2002	AT	266394 T	15-05-2004
			AU	749699 B2	04-07-2002
			AU	2529299 A	23-08-1999
			BR	9907689 A	14-11-2000
			CA	2320476 A1	12-08-1999
			CN	1298299 T	06-06-2001
			DE	69917221 D1	17-06-2004
			DK	1052984 T3	20-09-2004
			EP	1052984 A1	22-11-2000
			GB	2349884 A	15-11-2000
			WO	9939704 A1	12-08-1999
			HU	0102901 A2	28-12-2001
			JP	2002502815 T	29-01-2002
			NO	20003969 A	28-09-2000
			NZ	505675 A	26-11-2002
			NZ	521033 A	31-10-2003
			PL	342296 A1	04-06-2001
TR	200002311 T2	21-11-2000			
US	2002165167 A1	07-11-2002			

BEST AVAILABLE COPY